$1.19
+0.06 (+5.31%)
Open$1.16
Previous Close$1.13
Day High$1.20
Day Low$1.15
52W High$1.94
52W Low$0.66
Volume—
Avg Volume1.64M
Market Cap134.87M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+383.2% upside
Current
$1.19
$1.19
Target
$5.75
$5.75
$4.43
$5.75 avg
$6.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.18M | 15.06M | 39.14M |
| Net Income | -126,851,064 | -278,317,790 | -10,010,485 |
| Profit Margin | -2,051.1% | -1,948.5% | -25.6% |
| EBITDA | -125,358,699 | -290,323,656 | -16,322,152 |
| Free Cash Flow | — | — | -10,981,777 |
| Rev Growth | -59.0% | -59.0% | +22.5% |
| Debt/Equity | — | — | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |